Midday Glance: Biotechnology companies
AP - Tue May 13, 12:43PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
Early Glance: Biotechnology companies
AP - Tue May 13, 9:41AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
Clinical Trial Results, Acquisitions, Healthcare Partnership, and Pricing of Senior Notes - Analyst Notes on Merck, JNJ, Chelsea, Unitedhealth and Celgene
PR Newswire - Tue May 13, 6:20AM CDT
Today, Analysts Review released its analysts' notes regarding Merck & Co. Inc. (NYSE: MRK), Johnson & Johnson (NYSE: JNJ), Chelsea Therapeutics International Ltd. (NASDAQ: CHTP), Unitedhealth Group, Inc. (NYSE: UNH) and Celgene Corporation (NASDAQ: CELG). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2377-100free.
Final Glance: Biotechnology companies
AP - Mon May 12, 5:02PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were up at the close of trading:
Celgene Rises 2.63% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Mon May 12, 4:00PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $145.70 to a high of $151.00. Yesterday, the shares gained 2.6%, which took the trading range above the 3-day high of $147.99 on volume of 3.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
After Yesterday's Rally of 2.63% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Mon May 12, 3:59PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $145.70 to a high of $151.00. Yesterday, the shares gained 2.6%, which took the trading range above the 3-day high of $147.99 on volume of 3.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Will Patterson (PDCO) Disappoint this Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon May 12, 12:00PM CDT
Patterson's (PDCO) bottom-line growth was on par with the Zacks Consensus Estimate.
Celgene Earnings Review: 18 Days after Announcement Shares Up 3.8% (CELG)
Comtex SmarTrend(R) - Mon May 12, 11:09AM CDT
When Celgene (NASDAQ:CELG) reported earnings 18 days ago on April 24th, 2014, analysts, on average, expected the company to report earnings of $1.65 on sales of $1.8 billion. The company actually reported EPS of $1.67 on sales of $1.7 billion, beating EPS estimates by $0.02 and missing revenue estimates by $35.1 million. Shares of Celgene have climbed from $141.25 to $146.67, representing a gain of 3.8% since the company reported earnings 18 days ago.
Here's What These $3 Billion Money Managers Have Been Buying
Selena Maranjian, The Motley Fool - Motley Fool - Mon May 12, 10:05AM CDT
Every quarter, many money managers have to disclose what they've bought and sold via "13F" filings. Their latest moves can shine a bright light on smart stock picks. Today, let's look at Todd Asset Management. Based in Kentucky, the money managers'...
Visualizing Biotech P/E Compression and Why It's a Buy Signal
at The Street - Mon May 12, 9:19AM CDT
J.P. Morgan analyst Geoff Meacham issued a cautiously optimistic note about the biotech sector this morning. While investor sentiment remains "fragile," and volatility continues to be high, Meacham believes the worst of the selling is over.
2014 FDA Drug Approval Calendar
at The Street - Mon May 12, 8:22AM CDT
A list of drugs under FDA review and scheduled FDA advisory panel meetings.
How This 1 Company Is Attempting to Overcome One of Cancer's Greatest Risk Factors
Sean Williams, The Motley Fool - Motley Fool - Sat May 10, 1:05PM CDT
Cancer is one of the scariest disease diagnoses imaginable, at least according to one U.K. study , and that's primarily because researchers, despite decades of work and collaboration, are still scratching the surface on what triggers cancer in the...
Why Agios Pharmaceuticals Inc. Shares Flopped
Sean Williams, The Motley Fool - Motley Fool - Thu May 08, 5:08PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Agios Pharmaceuticals , a clinical-stage...
Investor's Corner: How To Use The Big Cap 20
at Investor's Business Daily - Thu May 08, 3:09PM CDT
As IBD stock screens go, the IBD Big Cap 20 is of a different stripe. A primary focus on large-capitalization stocks distinguishes it from the high-growth slant of the IBD 50 or Your Weekly Review. But that doesn't mean that the IBD Big Cap 20, which...